Celgene Corp. (CELG)

Sector:Health Care
Super Investor Stats:
Ownership count:0
Ownership rank:--
% of all portfolios:0%
History Portfolio Manager Activity Share change % change to portfolio
Q1  2019
David Abrams - Abrams Capital Management Buy 6,752,869 17.89
Seth Klarman - Baupost Group Buy 4,000,000 3.27
Daniel Loeb - Third Point Buy 1,750,000 1.85
Prem Watsa - Fairfax Financial Holdings Buy 14,500 0.07
Q4  2018
Meridian Contrarian Fund Add 34.75% 41,000 0.52
Bill Miller - Miller Value Partners Add 0.51% 4,250 0.01
Q3  2018
Meridian Contrarian Fund Add 34.09% 30,000 0.41
Bill Miller - Miller Value Partners Add 19.04% 133,040 0.40
Q2  2018
Bill Miller - Miller Value Partners Add 68.80% 284,850 0.87
Q1  2018
Bill Miller - Miller Value Partners Add 18720.68% 411,855 1.61
Meridian Contrarian Fund Add 14.19% 22,000 0.32
Q4  2017
David Rolfe - Wedgewood Partners Add 42.19% 285,542 1.20
Meridian Contrarian Fund Add 15.67% 21,000 0.36
Thomas Russo - Gardner Russo & Quinn Buy 500 0.00
Q2  2017
David Rolfe - Wedgewood Partners Add 316.36% 607,402 2.42
Lee Ainslie - Maverick Capital Buy 19,150 0.03
Bill Miller - Miller Value Partners Buy 2,200 0.01
Q1  2017
Meridian Contrarian Fund Add 10.74% 13,000 0.31
David Rolfe - Wedgewood Partners Buy 192,000 0.62
Q2  2016
Meridian Contrarian Fund Add 36.04% 40,000 0.79
Q1  2016
Lee Ainslie - Maverick Capital Add 105.88% 2,520 0.01
Meridian Contrarian Fund Add 4.72% 5,000 0.10
Q4  2015
Lee Ainslie - Maverick Capital Add 13.88% 290 0.00
Meridian Contrarian Fund Buy 106,000 2.33
Q1  2015
Lee Ainslie - Maverick Capital Buy 2,230 0.00

* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.